尿路感染症(UTI)治療の世界市場:産業分析・機会分析

◆英語タイトル:Urinary Tract Infection Treatment Market: Global Industry Analysis and Opportunity Assessment, 2016 - 2026
◆商品コード:FMI609184
◆発行会社(調査会社):Future Market Insights
◆発行日:2016年6月23日
◆ページ数:229
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,140,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。



※本調査レポートでは、尿路感染症(UTI)治療の世界市場について調査・分析し、市場概観、尿路感染症(UTI)治療の世界市場規模、市場規模予測、地域別分析(アメリカ、ヨーロッパ、アジア等)、セグメント別市場分析、競争状況、尿路感染症(UTI)治療市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

Future Market Insights (FMI) offers a 10-year forecast on the urinary tract infection treatment market between 2016 and 2026. In terms of value, the urinary tract infection treatment market is expected to register a CAGR of 2.1% during the forecast period. This study demonstrates market dynamics and trends in major global countries that are expected to influence the current environment and future status of the urinary tract infection treatment market over the forecast period.
Report Description

This report examines the urinary tract infection treatment market for the period 2016–2026. The primary objective of the report is to offer insights into developments in the urinary tract infection treatment market that are significantly helping transform the healthcare industry into a more comprehensive industry.

The urinary tract infection treatment market report begins by defining urinary tract infection and its drug types. It also lists the various indications for urinary tract infections. This is followed by an overview of the urinary tract infection treatment market. The overview section includes FMI’s analysis of key trends, drivers, restraints, and opportunities that are influencing growth of the global urinary tract infection treatment market currently. Impact analysis of the key growth drivers and restraints based on the weighted average model has also been included in the ‘report to better equip clients with country-specific trends and insights.

The primary driving factors for growth of the urinary tract infection treatment market include significant rising incidence of UTIs and recurring of UTIs, increasing use of urinary catheters and other drainage devices, and increasing incidence of chronic diseases. Furthermore, well established supply chain and ease of market distribution has also triggered growth of the global urinary tract infection treatment market.

On the basis of drug type, the urinary tract infection treatment market is segmented into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, and other segment. Penicillin & combinations segment is further sub-segmented into amoxicillin, amoxicillin & clavulanate potassium, and others. Quinolones segment is further sub-segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, and others. Cephalosporin segment is further sub-segmented into ceftriaxone, cefuroxime, cefixime, and cephalexin. Aminoglycoside antibodies segment is further sub-segmented into amikacin and gentamicin. On the basis of indication, the market is segmented complicated urinary tract infection, recurring complicated urinary tract infection, uncomplicated urinary tract infection, and neurogenic bladder infections. A detailed analysis of all categories of application has been provided in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and BPS analysis.

The next section of the report highlights the global urinary tract infection treatment market by region. It provides market outlook for 2016–2026 and sets the forecast within the context of the urinary tract infection treatment market. The study discusses the key regional trends and contracts contributing to growth of the urinary tract infection treatment market across the globe, as well as analyses the extent to which the drivers are influencing this market in these regions. Key markets assessed in this report include North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan, and MEA.

The above sections – by drug type, indication, distribution channel, and regional presence evaluate the present scenario and growth prospects of the urinary tract infection treatment market for the period 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e. 2016–2026.

The forecast presented here assesses the total revenue generated across the urinary tract infection treatment market globally over the forecast period. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the urinary tract infection treatment market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome on the basis of three different types of analysis, i.e. by supply side, downstream industry demand, and economic envelope.

It is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the global urinary tract infection treatment market and to identify the right opportunities the market presents.

The global urinary tract infection treatment market segments in terms of drug type, indication type, distribution channel, and regional presence are analysed on the basis of their respective Basis Point (BPS) to understand the individual segment’s relative contribution to market growth. This detailed level of information is important for identification of various key trends in the respective market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective.

To understand key growth segments, FMI has developed the market ‘Attractiveness Index’. The resulting index helps providers to identify real market opportunities.

In the final section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, to get a firm understanding of the key differentiators among competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. This section also includes market strategies and SWOT analysis of the main players in the market.

Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F.Hoffmann-La Roche Ltd., Novartis AG. and AstraZeneca plc.

Key Segments Covered

Drug Type
Penicillin & Combinations
Amoxicillin
Amoxicillin & Clavulanate Potassium
Others
Quinolones
Ciprofloxacin
Levofloxacin
Nalidixic acid
Norfloxacin
Others
Cephalosporin
Ceftriaxone
Cefuroxime
Cefixime
Cephalexin
Aminoglycoside antibiotics
Amikacin
Gentamicin
Sulphonamides
Azoles and Amphotericin B
Tetracycline
Nitrofurans
Other
By Indication
Complicated UTI
Recurring Complicated UTI
Uncomplicated UTI
Neurogenic Bladder Infections
By Distribution Channel
Hospital Pharmacies
Gynaecology and Urology Clinics
Drug Store
Retail Pharmacies
Online Drug Stores

Key Regions Covered

North America
Latin America
Western Europe
Eastern Europe
APEJ
Japan
MEA

Key Companies

Johnson and Johnsons Private Ltd.
Boehringer Ingelheim GmbH
Cipla Ltd.
Bayer AG
GlaxoSmithKline Pharmaceuticals Ltd.
Pfizer Inc.
Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca plc.

【レポートの目次】

Table Of Content

1.Assumptions and Acronyms Used

2.Research Methodology

3.Executive Summary

4.Urinary Tract Infection Treatment Market Overview

4.1. Introduction

4.1.1.Urinary Tract Infection Treatment Market Taxonomy

4.1.2.Urinary Tract Infection Treatment Market Definition

4.1.3.Urinary Tract Infection Treatment Market Drug Type Overview

4.1.4.Global Antibiotic Drugs Availability and Resistant Timeline

4.1.5.Clinical Trials

4.2. Urinary Tract Infection Treatment Market Dynamics

4.2.1.Drivers

4.2.2.Restraints

4.2.3.Opportunity

4.2.4.Trends

4.3. Survey Analysis

4.4. Epidemiology Overview

4.5. PEST Analysis

5.Global Urinary Tract Infection Treatment Market Analysis, By Drug Type

5.1. Introduction

5.1.1.Y-o-Y Growth Comparison, By Drug Type

5.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

5.1.3.Market Attractiveness Analysis, By Drug Type

5.2. Market Forecast, By Drug Type

5.2.1.Penicillin & Combinations

5.2.1.1. Absolute $ Opportunity

5.2.1.2. Market Value Forecast

5.2.1.3. Amoxicillin

5.2.1.4. Amoxicillin+ Clavulanate Potassium

5.2.1.5. Others

5.2.2.Quinolones

5.2.2.1. Absolute $ Opportunity

5.2.2.2. Market Value Forecast

5.2.2.3. Ciprofloxacin

5.2.2.4. Levofloxacin

5.2.2.5. Nalidixic acid

5.2.2.6. Norfloxacin

5.2.2.7. Others

5.2.3.Cephalosporin

5.2.3.1. Absolute $ Opportunity

5.2.3.2. Market Value Forecast

5.2.3.3. Cefuroxime

5.2.3.4. Ceftriaxone

5.2.3.5. Cefixime

5.2.3.6. Cephalexin

5.2.4.Aminoglycoside Antibiotics

5.2.4.1. Absolute $ Opportunity

5.2.4.2. Market Value Forecast

5.2.4.3. Amikacin

5.2.4.4. Gentamicin

5.2.5.Sulphonamides

5.2.5.1. Absolute $ Opportunity

5.2.5.2. Market Value Forecast

5.2.5.3. Sulfamethoxazole + Trimethoprim

5.2.6.Azoles and Amphotericin B

5.2.6.1. Absolute $ Opportunity

5.2.6.2. Market Value Forecast

5.2.7.Tetracycline

5.2.7.1. Absolute $ Opportunity

5.2.7.2. Market Value Forecast

5.2.7.3. Doxycycline

5.2.8.Nitrofurans

5.2.8.1. Absolute $ Opportunity

5.2.8.2. Market Value Forecast

5.2.8.3. Nitrofurantoin

5.2.9.Others

5.2.9.1. Absolute $ Opportunity

5.2.9.2. Market Value Forecast

6.Global Urinary Tract Infection Treatment Market Analysis, By Distribution Channel

6.1. Introduction

6.1.1.Y-o-Y Growth Comparison, By Distribution Channel

6.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

6.1.3.Market Attractiveness Analysis, By Distribution Channel

6.2. Market Forecast, By Distribution Channel

6.2.1.Hospital Pharmacies

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value Forecast

6.2.2.Gynecology and Urology Clinics

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value Forecast

6.2.3.Drug Store

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value Forecast

6.2.4.Retail Pharmacies

6.2.4.1. Absolute $ Opportunity

6.2.4.2. Market Value Forecast

6.2.5.Online Drug Stores

6.2.5.1. Absolute $ Opportunity

6.2.5.2. Market Value Forecast

7.Global Urinary Tract Infection Treatment Market Analysis, By Indication

7.1. Introduction

7.1.1.Y-o-Y Growth Comparison, By Distribution Channel

7.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

7.1.3.Market Attractiveness Analysis, By Distribution Channel

7.2. Market Forecast, By Distribution Channel

7.2.1.Complicated UTI

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value Forecast

7.2.2.Recurring Complicated UTI

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value Forecast

7.2.3.Uncomplicated UTI

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value Forecast

7.2.4.Neurogenic Bladder Infections

7.2.4.1. Absolute $ Opportunity

7.2.4.2. Market Value Forecast

7.2.4.3.

8.Global Urinary Tract Infection Treatment Market Analysis, By Region

8.1. Introduction

8.1.1.Y-o-Y Growth Projections, By Region

8.1.2.Market Share & Basis Point (BPS) Analysis, By Region

8.1.3.Regional Attractiveness Analysis

8.2. Market Forecast, By Region

8.2.1.North America Market Value Forecast

8.2.2.Latin America Market Value Forecast

8.2.3.Europe Market Value Forecast

8.2.4.Eastern Europe Market Value Forecast

8.2.5.APEJ Market Value Forecast

8.2.6.Japan Market Value Forecast

8.2.7.MEA Market Value Forecast

9.North America Urinary Tract Infection Treatment Market Analysis

9.1. Market Value Forecast, By Country

9.1.1.Y-o-Y Growth Projections, By Country

9.1.2.Market Share & Basis Point (BPS) Analysis, By Country

9.1.3.Market Attractiveness Analysis, By Country

9.1.4.US

9.1.5.Canada

9.2. Market Value Forecast, By Drug Type

9.2.1.Y-o-Y Growth Projections, By Drug Type

9.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

9.2.3.Market Attractiveness Analysis, By Drug Type

9.2.4.Penicillin & Combinations

9.2.4.1. Amoxicillin

9.2.4.2. Amoxicillin+ Clavulanate Potassium

9.2.4.3. Others

9.2.5.Quinolones

9.2.5.1. Ciprofloxacin

9.2.5.2. Levofloxacin

9.2.5.3. Nalidixic acid

9.2.5.4. Norfloxacin

9.2.5.5. Others

9.2.6.Cephalosporin

9.2.6.1. Cefuroxime

9.2.6.2. Ceftriaxone

9.2.6.3. Cefixime

9.2.6.4. Cephalexin

9.2.7.Aminoglycoside Antibiotics

9.2.7.1. Amikacin

9.2.7.2. Gentamicin

9.2.8.Sulphonamides

9.2.8.1. Sulfamethoxazole + Trimethoprim

9.2.9.Azoles and Amphotericin B

9.2.10.Tetracycline

9.2.10.1. Doxycycline

9.2.11.Nitrofurans

9.2.11.1. Nitrofurantoin

9.2.12.Others

9.3. Market Value Forecast, By Distribution Channel

9.3.1.Y-o-Y Growth Projections, By Distribution Channel

9.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

9.3.3.Market Attractiveness Analysis, By Distribution Channel

9.3.4.Hospital Pharmacies

9.3.5.Gynecology and Urology Clinics

9.3.6.Drug Stores

9.3.7.Retail Pharmacies

9.3.8.Online Drug Stores

9.4. Market Value Forecast, By Indication

9.4.1.Y-o-Y Growth Projections, By Indication

9.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

9.4.3.Market Attractiveness Analysis, By Indication

9.4.4.Complicated UTI

9.4.5.Recurring Complicated UTI

9.4.6.Uncomplicated UTI

9.4.7.Neurogenic Bladder Infections

10. Latin America Urinary Tract Infection Treatment Market Analysis

10.1. Market Value Forecast, By Country

10.1.1.Y-o-Y Growth Projections, By Country

10.1.2.Market Share & Basis Point (BPS) Analysis, By Country

10.1.3.Market Attractiveness Analysis, By Country

10.1.4.Brazil

10.1.5.Mexico

10.1.6.Rest of Latin America

10.2. Market Value Forecast, By Drug Type

10.2.1.Y-o-Y Growth Projections, By Drug Type

10.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

10.2.3.Market Attractiveness Analysis, By Drug Type

10.2.4.Penicillin & Combinations

10.2.4.1. Amoxicillin

10.2.4.2. Amoxicillin+ Clavulanate Potassium

10.2.4.3. Others

10.2.5.Quinolones

10.2.5.1. Ciprofloxacin

10.2.5.2. Levofloxacin

10.2.5.3. Nalidixic acid

10.2.5.4. Norfloxacin

10.2.5.5. Others

10.2.6.Cephalosporin

10.2.6.1. Cefuroxime

10.2.6.2. Ceftriaxone

10.2.6.3. Cefixime

10.2.6.4. Cephalexin

10.2.7.Aminoglycoside Antibiotics

10.2.7.1. Amikacin

10.2.7.2. Gentamicin

10.2.8.Sulphonamides

10.2.8.1. Sulfamethoxazole + Trimethoprim

10.2.9.Azoles and Amphotericin B

10.2.10. Tetracycline

10.2.10.1.Doxycycline

10.2.11. Nitrofurans

10.2.11.1.Nitrofurantoin

10.2.12. Others

10.3. Market Value Forecast, By Distribution Channel

10.3.1.Y-o-Y Growth Projections, By Distribution Channel

10.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

10.3.3.Market Attractiveness Analysis, By Distribution Channel

10.3.4.Hospital Pharmacies

10.3.5.Gynecology and Urology Clinics

10.3.6.Drug Stores

10.3.7.Retail Pharmacies

10.3.8.Online Drug Stores

10.4. Market Value Forecast, By Indication

10.4.1.Y-o-Y Growth Projections, By Indication

10.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

10.4.3.Market Attractiveness Analysis, By Indication

10.4.4.Complicated UTI

10.4.5.Recurring Complicated UTI

10.4.6.Uncomplicated UTI

10.4.7.Neurogenic Bladder Infections

11. Western Europe Urinary Tract Infection Treatment Market Analysis

11.1. Market Value Forecast, By Country

11.1.1.Y-o-Y Growth Projections, By Country

11.1.2.Market Share & Basis Point (BPS) Analysis, By Country

11.1.3.Market Attractiveness Analysis, By Country

11.1.4.UK

11.1.5.Germany

11.1.6.France

11.1.7.Spain

11.1.8.Italy

11.1.9.Nordic

11.1.10. Benelux

11.1.11. Rest of Western Europe

11.2. Market Value Forecast, By Drug Type

11.2.1.Y-o-Y Growth Projections, By Drug Type

11.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

11.2.3.Market Attractiveness Analysis, By Drug Type

11.2.4.Penicillin & Combinations

11.2.4.1. Amoxicillin

11.2.4.2. Amoxicillin+ Clavulanate Potassium

11.2.4.3. Others

11.2.5.Quinolones

11.2.5.1. Ciprofloxacin

11.2.5.2. Levofloxacin

11.2.5.3. Nalidixic acid

11.2.5.4. Norfloxacin

11.2.5.5. Others

11.2.6.Cephalosporin

11.2.6.1. Cefuroxime

11.2.6.2. Ceftriaxone

11.2.6.3. Cefixime

11.2.6.4. Cephalexin

11.2.7.Aminoglycoside Antibiotics

11.2.7.1. Amikacin

11.2.7.2. Gentamicin

11.2.8.Sulphonamides

11.2.8.1. Sulfamethoxazole + Trimethoprim

11.2.9.Azoles and Amphotericin B

11.2.10. Tetracycline

11.2.10.1.Doxycycline

11.2.11. Nitrofurans

11.2.11.1.Nitrofurantoin

11.2.12. Others

11.3. Market Value Forecast, By Distribution Channel

11.3.1.Y-o-Y Growth Projections, By Distribution Channel

11.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

11.3.3.Market Attractiveness Analysis, By Distribution Channel

11.3.4.Hospital Pharmacies

11.3.5.Gynecology and Urology Clinics

11.3.6.Drug Stores

11.3.7.Retail Pharmacies

11.3.8.Online Drug Stores

11.4. Market Value Forecast, By Indication

11.4.1.Y-o-Y Growth Projections, By Indication

11.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

11.4.3.Market Attractiveness Analysis, By Indication

11.4.4.Complicated UTI

11.4.5.Recurring Complicated UTI

11.4.6.Uncomplicated UTI

11.4.7.Neurogenic Bladder Infections

12. Eastern Europe Urinary Tract Infection Treatment Market Analysis

12.1. Market Value Forecast, By Country

12.1.1.Y-o-Y Growth Projections, By Country

12.1.2.Market Share & Basis Point (BPS) Analysis, By Country

12.1.3.Market Attractiveness Analysis, By Country

12.1.4.Russia

12.1.5.Poland

12.1.6.Rest of Eastern Europe

12.2. Market Value Forecast, By Drug Type

12.2.1.Y-o-Y Growth Projections, By Drug Type

12.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

12.2.3.Market Attractiveness Analysis, By Drug Type

12.2.4.Penicillin & Combinations

12.2.4.1. Amoxicillin

12.2.4.2. Amoxicillin+ Clavulanate Potassium

12.2.4.3. Others

12.2.5.Quinolones

12.2.5.1. Ciprofloxacin

12.2.5.2. Levofloxacin

12.2.5.3. Nalidixic acid

12.2.5.4. Norfloxacin

12.2.5.5. Others

12.2.6.Cephalosporin

12.2.6.1. Cefuroxime

12.2.6.2. Ceftriaxone

12.2.6.3. Cefixime

12.2.6.4. Cephalexin

12.2.7.Aminoglycoside Antibiotics

12.2.7.1. Amikacin

12.2.7.2. Gentamicin

12.2.8.Sulphonamides

12.2.8.1. Sulfamethoxazole + Trimethoprim

12.2.9.Azoles and Amphotericin B

12.2.10. Tetracycline

12.2.10.1.Doxycycline

12.2.11. Nitrofurans

12.2.11.1.Nitrofurantoin

12.2.12. Others

12.3. Market Value Forecast, By Distribution Channel

12.3.1.Y-o-Y Growth Projections, By Distribution Channel

12.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

12.3.3.Market Attractiveness Analysis, By Distribution Channel

12.3.4.Hospital Pharmacies

12.3.5.Gynecology and Urology Clinics

12.3.6.Drug Stores

12.3.7.Retail Pharmacies

12.3.8.Online Drug Stores

12.4. Market Value Forecast, By Indication

12.4.1.Y-o-Y Growth Projections, By Indication

12.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

12.4.3.Market Attractiveness Analysis, By Indication

12.4.4.Complicated UTI

12.4.5.Recurring Complicated UTI

12.4.6.Uncomplicated UTI

12.4.7.Neurogenic Bladder Infections

13. APEJ Urinary Tract Infection Treatment Market Analysis

13.1. Market Value Forecast, By Country

13.1.1.Y-o-Y Growth Projections, By Country

13.1.2.Market Share & Basis Point (BPS) Analysis, By Country

13.1.3.Market Attractiveness Analysis, By Country

13.1.4.China

13.1.5.India

13.1.6.ASEAN

13.1.7.Australia & New Zealand

13.1.8.Rest of APEJ

13.2. Market Value Forecast, By Drug Type

13.2.1.Y-o-Y Growth Projections, By Drug Type

13.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

13.2.3.Market Attractiveness Analysis, By Drug Type

13.2.4.Penicillin & Combinations

13.2.4.1. Amoxicillin

13.2.4.2. Amoxicillin+ Clavulanate Potassium

13.2.4.3. Others

13.2.5.Quinolones

13.2.5.1. Ciprofloxacin

13.2.5.2. Levofloxacin

13.2.5.3. Nalidixic acid

13.2.5.4. Norfloxacin

13.2.5.5. Others

13.2.6.Cephalosporin

13.2.6.1. Cefuroxime

13.2.6.2. Ceftriaxone

13.2.6.3. Cefixime

13.2.6.4. Cephalexin

13.2.7.Aminoglycoside Antibiotics

13.2.7.1. Amikacin

13.2.7.2. Gentamicin

13.2.8.Sulphonamides

13.2.8.1. Sulfamethoxazole + Trimethoprim

13.2.9.Azoles and Amphotericin B

13.2.10. Tetracycline

13.2.10.1.Doxycycline

13.2.11. Nitrofurans

13.2.11.1.Nitrofurantoin

13.2.12. Others

13.3. Market Value Forecast, By Distribution Channel

13.3.1.Y-o-Y Growth Projections, By Distribution Channel

13.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

13.3.3.Market Attractiveness Analysis, By Distribution Channel

13.3.4.Hospital Pharmacies

13.3.5.Gynecology and Urology Clinics

13.3.6.Drug Stores

13.3.7.Retail Pharmacies

13.3.8.Online Drug Stores

13.4. Market Value Forecast, By Indication

13.4.1.Y-o-Y Growth Projections, By Indication

13.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

13.4.3.Market Attractiveness Analysis, By Indication

13.4.4.Complicated UTI

13.4.5.Recurring Complicated UTI

13.4.6.Uncomplicated UTI

13.4.7.Neurogenic Bladder Infections

14. Japan Urinary Tract Infection Treatment Market Analysis

14.1. Market Value Forecast, By Drug Type

14.1.1.Y-o-Y Growth Projections, By Drug Type

14.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

14.1.3.Market Attractiveness Analysis, By Drug Type

14.1.4.Penicillin & Combinations

14.1.4.1. Amoxicillin

14.1.4.2. Amoxicillin+ Clavulanate Potassium

14.1.4.3. Others

14.1.5.Quinolones

14.1.5.1. Ciprofloxacin

14.1.5.2. Levofloxacin

14.1.5.3. Nalidixic acid

14.1.5.4. Norfloxacin

14.1.5.5. Others

14.1.6.Cephalosporin

14.1.6.1. Cefuroxime

14.1.6.2. Ceftriaxone

14.1.6.3. Cefixime

14.1.6.4. Cephalexin

14.1.7.Aminoglycoside Antibiotics

14.1.7.1. Amikacin

14.1.7.2. Gentamicin

14.1.8.Sulphonamides

14.1.8.1. Sulfamethoxazole + Trimethoprim

14.1.9.Azoles and Amphotericin B

14.1.10. Tetracycline

14.1.10.1.Doxycycline

14.1.11. Nitrofurans

14.1.11.1.Nitrofurantoin

14.1.12. Others

14.2. Market Value Forecast, By Distribution Channel

14.2.1.Y-o-Y Growth Projections, By Distribution Channel

14.2.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

14.2.3.Market Attractiveness Analysis, By Distribution Channel

14.2.4.Hospital Pharmacies

14.2.5.Gynecology and Urology Clinics

14.2.6.Drug Stores

14.2.7.Retail Pharmacies

14.2.8.Online Drug Stores

14.3. Market Value Forecast, By Indication

14.3.1.Y-o-Y Growth Projections, By Indication

14.3.2.Market Share & Basis Point (BPS) Analysis, By Indication

14.3.3.Market Attractiveness Analysis, By Indication

14.3.4.Complicated UTI

14.3.5.Recurring Complicated UTI

14.3.6.Uncomplicated UTI

14.3.7.Neurogenic Bladder Infections

15. MEA Urinary Tract Infection Treatment Market Analysis

15.1. Market Value Forecast, By Country

15.1.1.Y-o-Y Growth Projections, By Country

15.1.2.Market Share & Basis Point (BPS) Analysis, By Country

15.1.3.Market Attractiveness Analysis, By Country

15.1.4.GCC Countries

15.1.5.South Africa

15.1.6.North Africa

15.1.7.Rest of MEA

15.2. Market Value Forecast, By Drug Type

15.2.1.Y-o-Y Growth Projections, By Drug Type

15.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

15.2.3.Market Attractiveness Analysis, By Drug Type

15.2.4.Penicillin & Combinations

15.2.4.1. Amoxicillin

15.2.4.2. Amoxicillin+ Clavulanate Potassium

15.2.4.3. Others

15.2.5.Quinolones

15.2.5.1. Ciprofloxacin

15.2.5.2. Levofloxacin

15.2.5.3. Nalidixic acid

15.2.5.4. Norfloxacin

15.2.5.5. Others

15.2.6.Cephalosporin

15.2.6.1. Cefuroxime

15.2.6.2. Ceftriaxone

15.2.6.3. Cefixime

15.2.6.4. Cephalexin

15.2.7.Aminoglycoside Antibiotics

15.2.7.1. Amikacin

15.2.7.2. Gentamicin

15.2.8.Sulphonamides

15.2.8.1. Sulfamethoxazole + Trimethoprim

15.2.9.Azoles and Amphotericin B

15.2.10. Tetracycline

15.2.10.1.Doxycycline

15.2.11. Nitrofurans

15.2.11.1.Nitrofurantoin

15.2.12. Others

15.3. Market Value Forecast, By Distribution Channel

15.3.1.Y-o-Y Growth Projections, By Distribution Channel

15.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel

15.3.3.Market Attractiveness Analysis, By Distribution Channel

15.3.4.Hospital Pharmacies

15.3.5.Gynecology and Urology Clinics

15.3.6.Drug Stores

15.3.7.Retail Pharmacies

15.3.8.Online Drug Stores

15.4. Market Value Forecast, By Indication

15.4.1.Y-o-Y Growth Projections, By Indication

15.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

15.4.3.Market Attractiveness Analysis, By Indication

15.4.4.Complicated UTI

15.4.5.Recurring Complicated UTI

15.4.6.Uncomplicated UTI

15.4.7.Neurogenic Bladder Infections

16. Competition Landscape

16.1. Competition Dashboard

16.2. Company Profiles Inclusions

16.2.1.Revenue

16.2.2.Products/Brand Offerings

16.2.3.Key developments

16.2.4.SWOT Analysis

16.3. Company Profiled

16.3.1.Johnson & Johnson Private Ltd.

16.3.2.Boehringer Ingelheim GmbH

16.3.3.Cipla Ltd.

16.3.4.Bayer AG

16.3.5.GlaxoSmithKline Pharmaceuticals Ltd.

16.3.6.Pfizer Inc.

16.3.7.F. Hoffmann–La Roche Ltd.

16.3.8.Novartis AG

16.3.9.AstraZeneca plc



【レポートのキーワード】

尿路感染症、尿路感染症治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[尿路感染症(UTI)治療の世界市場:産業分析・機会分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月10日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆